Halozyme Therapeutics, Inc. (HALO) P/E Ratio History
Historical price-to-earnings valuation from 2017 to 2025
Loading P/E history...
HALO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Halozyme Therapeutics, Inc. (HALO) trades at a price-to-earnings ratio of 25.5x, with a stock price of $65.19 and trailing twelve-month earnings per share of $2.69.
The current P/E is 21% above its 5-year average of 21.1x. Over the past five years, HALO's P/E has ranged from a low of 11.9x to a high of 39.2x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, HALO is roughly in line with its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
The PEG ratio of 1.11 (P/E divided by -25% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, HALO trades roughly in line with the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HALO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HALO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 127.0 | - | +207% | |
| $12B | 16.6 | 0.32Best | +58% | |
| $2B | 6.9Lowest | 0.67 | +817%Best | |
| $358B | 85.5 | - | -1% | |
| $178B | 23.1 | 7.86 | +88% | |
| $74B | 17.1 | 2.70 | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
HALO Historical P/E Data (2017–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $67.30 | $2.49 | 27.0x | -15% |
| FY2025 Q3 | $73.34 | $4.75 | 15.4x | -51% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $52.02 | $4.37 | 11.9x | -63% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $63.81 | $3.76 | 17.0x | -47% |
| FY2024 Q4 | $47.81 | $3.43 | 13.9x | -56% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $57.24 | $3.02 | 19.0x | -40% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $52.36 | $2.58 | 20.3x | -36% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $40.68 | $2.42 | 16.8x | -47% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $36.96 | $2.11 | 17.5x | -45% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $38.20 | $1.88 | 20.3x | -36% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $36.07 | $1.71 | 21.1x | -34% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $38.19 | $1.31 | 29.2x | -8% |
Average P/E for displayed period: 31.8x
See HALO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HALO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HALO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHALO — Frequently Asked Questions
Quick answers to the most common questions about buying HALO stock.
Is HALO stock overvalued or undervalued?
HALO trades at 25.5x P/E, above its 5-year average of 21.1x. The 70th percentile ranking indicates a premium to historical valuation.
How does HALO's valuation compare to peers?
Halozyme Therapeutics, Inc. P/E of 25.5x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is HALO's PEG ratio?
HALO PEG ratio is 1.11. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 2017-2025.